Charles Schwab’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-302,463
| Closed | -$10.4M | – | 3440 |
|
|
2020
Q3 | $10.4M | Buy |
302,463
+12,344
| +4% | +$263K | ﹤0.01% | 1666 |
|
|
2020
Q2 | $4.85M | Buy |
290,119
+24,830
| +9% | +$422K | ﹤0.01% | 2047 |
|
|
2020
Q1 | $3.83M | Buy |
265,289
+3,471
| +1% | +$88.7K | ﹤0.01% | 1962 |
|
|
2019
Q4 | $8.76M | Buy |
261,818
+8,464
| +3% | +$237K | ﹤0.01% | 1722 |
|
|
2019
Q3 | $5.31M | Buy |
253,354
+17,553
| +7% | +$358K | ﹤0.01% | 1928 |
|
|
2019
Q2 | $4.91M | Buy |
235,801
+7,878
| +3% | +$162K | ﹤0.01% | 1982 |
|
|
2019
Q1 | $5.09M | Buy |
227,923
+10,019
| +5% | +$236K | ﹤0.01% | 1975 |
|
|
2018
Q4 | $5.21M | Buy |
217,904
+2,327
| +1% | +$60.2K | ﹤0.01% | 1886 |
|
|
2018
Q3 | $5.88M | Buy |
215,577
+8,322
| +4% | +$235K | ﹤0.01% | 1958 |
|
|
2018
Q2 | $5.57M | Buy |
207,255
+23,678
| +13% | +$725K | ﹤0.01% | 1939 |
|
|
2018
Q1 | $5.84M | Buy |
183,577
+45,129
| +33% | +$1.59M | ﹤0.01% | 1856 |
|
|
2017
Q4 | $5.24M | Buy |
138,448
+27,868
| +25% | +$899K | ﹤0.01% | 1897 |
|
|
2017
Q3 | $2.74M | Buy |
110,580
+4,891
| +5% | +$105K | ﹤0.01% | 2159 |
|
|
2017
Q2 | $2.17M | Buy |
105,689
+18,632
| +21% | +$355K | ﹤0.01% | 2197 |
|
|
2017
Q1 | $1.89M | Buy |
87,057
+4,788
| +6% | +$98.2K | ﹤0.01% | 2221 |
|
|
2016
Q4 | $1.68M | Buy |
82,269
+4,312
| +6% | +$88.1K | ﹤0.01% | 2248 |
|
|
2016
Q3 | $1.17M | Buy |
77,957
+25,963
| +50% | +$350K | ﹤0.01% | 2366 |
|
|
2016
Q2 | $563K | Buy |
51,994
+25,278
| +95% | +$343K | ﹤0.01% | 2549 |
|
|
2016
Q1 | $363K | Buy |
26,716
+459
| +2% | +$7.16K | ﹤0.01% | 2709 |
|
|
2015
Q4 | $485K | Buy |
26,257
+16,185
| +161% | +$299K | ﹤0.01% | 2656 |
|
|
2015
Q3 | $256K | Buy |
+10,072
| New | +$235K | ﹤0.01% | 2885 |
|
Charles Schwab's AIMT Position: Q4 2020 in Review
Charles Schwab sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 302,463 shares — an estimated $10.4M sold.
Charles Schwab first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $10.4M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Charles Schwab reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Charles Schwab sold 302,463 Aimmune Therapeutics shares in Q4 2020, an estimated $10.4M.
- Charles Schwab first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Charles Schwab's Aimmune Therapeutics position peaked at $10.4M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Charles Schwab's 13F filing for Q4 2020, filed 16 Feb 2021.